Drugs / Tc99m tilmanocept
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04096716 | Dec 2019 → Apr 2022 | central nervous system neoplasm | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03157167 | Dec 2017 → Nov 2019 | HIV infectious disease, Kaposi's sarcoma | Navidea Biopharmaceuticals | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07159074 | Sep 2025 → Dec 2026 expected | cardiac sarcoidosis | Duke University | Recruiting | No outcome recorded |
| Phase 2 | NCT04947137 | May 2021 → Jan 2022 | rheumatoid arthritis | Navidea Biopharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03938636 | Apr 2019 → Feb 2021 | rheumatoid arthritis | Navidea Biopharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02509585 | Jan 2016 → Jul 2017 | uterine cervix neoplasm | Cardinal Health 414, LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02509598 | Aug 2015 → Mar 2019 | melanoma, rhabdomyosarcoma | Cardinal Health 414, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tc99m-tilmanocept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03157167 ↗ |
| Modality | Diagnostic / imaging agent | “Lymphoseek in the detection of lymph nodes” NCT02509585 ↗ |
| Route | Other | “administered peritumorally” NCT02509585 ↗ |